The WHO goal of eliminating viral hepatitis by 2030 is in our reach, but a one-size-fits-all approach won’t work. The leadership of the people and communities most affected by viral hepatitis is critical. That’s why Gilead proudly supports grassroots organizations around the world to deliver innovative programs where they will have the greatest impact. Through programs like HepConnect and All4Liver we are seeing the people most affected by hepatitis to use their expertise-by-experience to achieve the 2030 goal. This webinar series highlights key learnings and best practices from our community partners, and the invaluable work they are doing to help eliminate viral hepatitis. Join Shanell McCoy and Amy O’Brien from Gilead’s Corporate Giving team as they introduce and give a brief overview of the first episode, focused on harm reduction, and why it is a vital tool in eliminating viral hepatitis. For more information about Gilead, visit: Website: https://www.gilead.com Stories@Gilead: https://stories.gilead.com Twitter: https://twitter.com/gileadsciences LinkedIn: https://linkedin.com/company/gileadsc... Instagram: https://www.instagram.com/gileadsciences Facebook: https://www.facebook.com/gileadsciences About Gilead Gilead Sciences, Inc. is a biopharmaceutical company that has pursued and achieved breakthroughs in medicine for more than three decades, with the goal of creating a healthier world for all people. The company is committed to advancing innovative medicines to prevent and treat life-threatening diseases, including HIV, viral hepatitis, COVID-19, and cancer. Gilead operates in more than 35 countries worldwide, with headquarters in Foster City, California. This webinar episode was created and fully funded by Gilead Sciences, Inc. GILEAD, the GILEAD logo, and the & design are trademarks of Gilead Sciences, Inc. © 2023 Gilead Sciences, Inc. All rights reserved.

 200